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http://dx.doi.org/10.1016/j.ccr.2013.02.014SUMMARYWhile all-trans retinoic acid (ATRA) treatment in acute promyelocytic leukemia (APL) has been the paradigm
of targeted therapy for oncogenic transcription factors, the underlying mechanisms remain largely unknown,
and a significant number of patients still relapse and become ATRA resistant. We identified the histone
demethylase PHF8 as a coactivator that is specifically recruited by RARa fusions to activate expression of
their downstream targets upon ATRA treatment. Forced expression of PHF8 resensitizes ATRA-resistant
APL cells, whereas its downregulation confers resistance. ATRA sensitivity depends on the enzymatic
activity and phosphorylation status of PHF8, which can be pharmacologically manipulated to resurrect
ATRA sensitivity to resistant cells. These findings provide important molecular insights into ATRA response
and a promising avenue for overcoming ATRA resistance.INTRODUCTION
Transcriptional deregulation plays a key role in a large array of
human malignancies, in particular, in acute leukemia, which is
mostly initiated by chimeric transcription factors (CTFs) that
induce oncogenic transcriptional programs resulting in cellular
transformation (Cheung and So, 2011). The successful applica-
tion of all-trans retinoic acid (ATRA) treatment to acute promye-
locytic leukemia (APL) induced by RARa fusion proteins repre-
sents a major breakthrough and is the paradigm for targeted
therapy of oncogenic transcription factors (Wang and Chen,
2008). In spite of its success in achieving a complete remissionSignificance
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376 Cancer Cell 23, 376–389, March 18, 2013 ª2013 Elsevier Inc.(CR), APL patients receiving ATRA treatment alone do not
achieve definite cure of the disease. Although refined APL
treatment regimens in combination with anthracycline-based
chemotherapy or arsenic trioxide (ATO) result in 90% of initial
CR, a significant proportion of patients still relapse and are
resistant to the treatment with 3 years overall survival in second
remission of only around 50% (Sanz and Lo-Coco, 2011). Also,
while the success of ATRA treatment in APL sets the stage for
targeted therapy of oncogenic transcription factors, retinoic
acid (RA) treatment is ineffective to other malignant diseases.
Therefore, understanding the molecular mechanisms of APL
pathogenesis and ATRA response are of major interest, becausecription factors and their associated epigenetic-modifying
evelopment of targeted therapy. In this study, we discover
or for mediating retinoic acid (RA) treatment response in
both the enzymatic activity and phosphorylation status of
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mic cells. These results reveal a critical function of histone
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ATRA resistance and potentially extend its application to other
malignancies.
Over the years, we and others have shown that RARa fusions
form high-order homo-oligomers (Kwok et al., 2006; Lin and
Evans, 2000; Minucci et al., 2000; Sternsdorf et al., 2006) that
aberrantly recruit DNA binding cofactor RXRa (Zeisig et al.,
2007; Zhu et al., 2007) and epigenetic modifying enzymes such
as histone deacetylases (HDACs) (Grignani et al., 1998; Lin
et al., 1998) and polycomb-repressive complexes (PRCs)
(Boukarabila et al., 2009; Smith et al., 2011; Villa et al., 2007)
for transcriptional suppression of their downstream targets
(e.g., RARB) and oncogenic transformation. A pharmacological
level of ATRA induces conformational changes of RARa fusions,
which result in dissociation of corepressor complexes and
recruitment of coactivators, leading to activation of downstream
targets and subsequent degradation of the fusion proteins (de
The´ andChen, 2010;Wang and Chen, 2008). In spite of its critical
functions in mediating ATRA response, the identity of the
coactivator complex responsible for gene activation upon
ATRA treatment remains unknown, and this becomes a major
hurdle that significantly hinders the progress in understanding
underlying mechanisms of ATRA response and designing more
effective therapeutic strategies for overcoming resistance
(Martens et al., 2010; Mikesch et al., 2010).
Emerging evidence indicates that dynamic histone modifica-
tions by lysine methyltransferases (KMTs) and demethylases
(KDMs) play a key role in regulation of gene expression
(Cheung and So, 2011; Kouzarides, 2007). Members of
Jumonji-C domain (JmjC) KDMs involved in diverse biological
processes including embryonic development, stem cell self-
renewal, and differentiation are known to work closely together
with specific KMTs by removing opposite epigenetic marks to
govern gene expression (Cheung and So, 2011; Kooistra and
Helin, 2012). PHF8 (also called KDM7B) is a member of the
plant homeodomain finger (PHF) family KDM harboring an
N-terminal plant homeodomain (PHD) that mediates binding
to nucleosomes at active gene promoters as well as an active
JmjC domain that is able to catalyze the demethylation of
mono- or dimethyl-lysines (Feng et al., 2010; Fortschegger
et al., 2010; Kleine-Kohlbrecher et al., 2010; Liu et al., 2010;
Loenarz et al., 2010; Qi et al., 2010). PHF8 preferentially acts
on H3K9me2 and H3K9me1 (however, some results also
suggest that it can demethylate H4K20me1) and associates
with transcriptional activation and retinoic acid signaling
pathway in neuronal differentiation (Qiu et al., 2010). Mutations
in the PHF8 gene are found in patients with X-linked mental
retardation (XLMR), and knockdown of PHF8 homolog leads
to brain defects in zebrafish (Abidi et al., 2007; Koivisto et al.,
2007; Laumonnier et al., 2005), revealing its potential involve-
ment in human disease.
RESULTS
PHF8 Interacts with PML-RARa and Functions
as a Transcriptional Coactivator in Response to
ATRA Treatment
Given the critical functions of JmjC-KDMs in transcriptional
regulation, we performed a systematic biochemical screeningby immunoprecipitation assay in human 293T cells for interac-
tions between PML-RARa and seven different JmjC-KDMs
from each of the subfamily (KDM2-7) with known enzymatic
activity upon ATRA treatment. As a result, we identified PHF8
as the only KDM that exhibited a highly specific interaction
with PML-RARa, and this interaction increased significantly in
the presence of ATRA (Figure 1A; data not shown). To validate
this finding in APL, we showed that endogenous PHF8 binds to
PML-RARa in human NB4 cells (Figure S1A available online),
which express the PML-RARa fusion.
To further characterize this interaction, a series of PML-RARa
and PHF8 mutants were constructed for structure/function
analyses to define the respective interaction domains. In con-
trast to the regions D (hinge region), E (ligand binding domain,
LDB), and F (unknown function) of the PML-RARa that were
dispensable for PHF8 interaction, the region C that partly over-
laps with the DNA binding domain in the PML-RARa fusion
was absolutely required for the recruitment of PHF8 (Figure 1B).
On the other hand, the JmjC domain but not the catalytic activity
of PHF8 was essential for the interaction with PML-RARa
(Figure 1C). In contrast, the PHD domain and the C-terminal
domain of PHF8 were not part of the PML-RARa-interacting
motif (Figure 1C). Consistent with the recent findings of its
involvement in retinoic acid signaling (Qiu et al., 2010), mapping
of the PML-RARa interaction domain to the region C suggests
a potential interaction between PHF8 and wild-type RARa. To
gain further insights into this issue, we revealed that PML-
RARa had a much higher ability than wild-type RARa to form
complex with PHF8 in the presence of ATRA (Figure 1D). More-
over, the interaction between wild-type RARa and PHF8 rapidly
dissociated under the stringent washing condition, while the one
between PML-RARa and PHF8 remained stable (Figure 1E).
Consistently, only the PML-RARa/PHF8 interaction could be de-
tected upon ATRA treatment even when wild-type RARa was
coexpressed at the almost identical level as PML-RARa in the
same cells with endogenous or ectopic expression of PHF8 (Fig-
ure 1F). Together these results indicate that PML-RARa is by far
the dominant PHF8 binding partner compared towild-type RARa
in response to the ATRA treatment.
To assess the effect of PHF8 expression on histone modifica-
tion, we ectopically expressed PHF8 in NB4 and 293T cells. As
shown in Figures 1G, 1H, and S1B, PHF8 expression resulted in
a significant reduction of H3K9me2 levels in NB4 and 293T
cells, consistent with its role in promoting transcriptional activa-
tion (Feng et al., 2010; Fortschegger et al., 2010; Kleine-
Kohlbrecher et al., 2010; Liu et al., 2010; Loenarz et al., 2010;
Qi et al., 2010). To further demonstrate that PHF8 is indeed
recruited by PML-RARa to activate expression of downstream
targets upon ATRA treatment in APL cells, chromatin immuno-
precipitation (ChIP) assays revealed specific binding of PHF8
to the promoter region of RARB, a RARa fusion target, but not
toGAPDH control, upon ATRA treatment in NB4 cells (Figure 1I).
Recruitment of PHF8 was also associated with a reduction of
the H3K9me2 repressive mark, increase in H3K4me3 and
H3K9Ac activation marks (Figure 1J), and an increased in
RARB mRNA level (Figure S1C). These results demonstrate
that PHF8 binds to and modifies the promoter regions of
PML-RARa targets for active gene expression in APL cells
upon ATRA treatment.Cancer Cell 23, 376–389, March 18, 2013 ª2013 Elsevier Inc. 377
Figure 1. Specific Interaction of PHF8 with PML-RARa Results in Alternation of Histone Marks of Transcriptional Targets in Response to
ATRA Treatment
(A–F) Representative coimmunoprecipitation (coIP) analysis in 293T cells coexpressing PML-RARa and Flag-tagged Jumonji family members cultured in the
presence or absence of ATRA (A). Deleted or point mutants of PML-RARa were coexpressed with PHF8 (B), or deleted or point mutants of PHF8 were coex-
pressed with His-PML-RARa (C); and all samples were processed in presence of ATRA. Black arrowheads indicate mutants that cannot interact. PML-RARa or/
and wild-type RARa were expressed with Flag-tagged PHF8 using the indicated amounts of expression vectors, and cells were treated with ATRA as indicated;
samples were processed under mild washing conditions (D) or stringent washing conditions (E and F). Asterisk indicates unspecific band.
(G) Immunoblotting of purified histone extracts from NB4 and NB4-PHF8 cells.
(H) Histone demethylase activity of YFP-tagged PHF8 protein in 293T cells was assessed by immunostaining using confocal microscopy. White arrowheads
indicate cells transfected with YFP-PHF8. Scale bar, 10 mm. Anti-H3K9me2 and anti-H3K9me3 antibodies were used.
(I and J) ChIP analysis of the binding of the endogenous PHF8 (I) and histone H3modifications (J) on typical RARERARB promoter region in human NB4 cells after
24 hr with or without 108 M ATRA.
Data representative of at least three independent experiments are shown (±SD, *p < 0.05, **p < 0.01). See also Figure S1.
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PHF8 Governs ATRA Response in APLPHF8 Sensitizes APL Cells to Physiological Levels of
ATRA
To investigate the functional significance of PML-RARa/PHF8
interaction in mediating cellular response to ATRA treatment,
we performed both gain-of-function and loss-of-function studies
using human NB4 cells and mouse primary hematopoietic cells
transformed by APL fusion proteins (Kwok et al., 2006; Zeisig378 Cancer Cell 23, 376–389, March 18, 2013 ª2013 Elsevier Inc.et al., 2007). NB4 cells are highly sensitive to pharmacological
concentrations (106 M) but only have a mild response to phys-
iological level (108 M) of ATRA as assessed by activation of
a RARa fusion target, RARB, and inhibition of transformation
(Figures S2A and S2B). Strikingly, forced expression of PHF8
in NB4 cells (Figures 2A, 2B, S2C, and S2D) or primary hemato-
poietic cells transformed by different RARa fusions, including
Figure 2. PHF8 Governs ATRA Sensitivity of APL Cells
(A–D) Typical p-iodonitrotetrazolium-violet (INT)-stained colony pictures and bar charts representing normalized colony number of human NB4 and K562 cells (A
and B) or murine primary bone marrow cells transformed by the indicated RARa fusion constructs (C and D) treated with and without indicated concentration of
ATRA. Black arrowheads indicate the lowest optimal ATRA concentration employed inmost of the subsequent studies. Representative data of three experiments
are shown (±SEM, **p < 0.01).
(E) Quantitative RT-PCR (qRT-PCR) analysis for RARB expression in the indicated cells.
(F–J) qRT-PCR (F and I) and western blot analysis (G and J) for PHF8 expression in cell transduced with specific human (F and G) or mouse (I and J) PHF8 shRNA.
Error bars indicate SD of at least three independent experiments. (H) Human NB4 cells or (K) murine primary bone marrow cells transformed by PLZF-RARawere
transduced with either shRNAs for specific PHF8 knockdown (KD) or scramble control before they were plated into methylcellulose medium in the absence or
presence of ATRA for colony formation assay.
Data representative of three experiments are shown (±SEM, *p < 0.05, **p < 0.01, ***p < 0.001). See also Figure S2.
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PHF8 Governs ATRA Response in APLPLZF-RARa-transformed cells that are usually more resistant
to ATRA treatment in the presence of the reciprocal RARa-PLZF
fusion (Guidez et al., 2007), significantly sensitized their
response to ATRA (Figures 2C, 2D, S2E, and S2F). This function
of PHF8 highly depended on the following: (1) its enzymatic
activity as a single-point mutation F279S on the catalytic domain
identified in X-linked mental retardation patients (Kleine-Kohl-
brecher et al., 2010; Koivisto et al., 2007) completely abolished
the enhanced ATRA sensitivity including colony suppression
(Figures 2A–2D and S2D), enhanced RARB expression (Figures
2E and S2G), and differentiation of APL cells (Figure S2H); and
(2) the presence of RARa fusions as expression of PHF8 had
no effect on the ATRA response in the control human K562
leukemic cells or E2A-PBX1-transformed primary cells (Figures2A–2E, S2G, and S2I), which expressed the same or even higher
levels of RARa protein compared with those in NB4 cells and
PML-RARa-transformed primary cells, respectively (Figure S2J).
Consistently, the levels of PML-RARa were much higher than
those of wild-type RARa in both NB4 and PML-RARa-trans-
formed cells (Figure S2J). Together with the competitive/dilution
assays in Figures 1D–1F, these results strongly suggest that
PML-RARa is the major and dominant mediator for the PHF8/
ATRA response.
To demonstrate a critical function of endogenous PHF8 in
governing ATRA response, we further confirmed the expression
of endogenous PHF8 in NB4, which was indeed much higher
than that in the ATRA-resistant variant, NB4-MR2 cells (Fig-
ure S2K), suggesting an association of ATRA resistance withCancer Cell 23, 376–389, March 18, 2013 ª2013 Elsevier Inc. 379
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PHF8 Governs ATRA Response in APLa reduced level of PHF8. To further validate this hypothesis,
endogenous PHF8 expression was downmodulated by small
hairpin RNAs (shRNAs) in human NB4 cells (Figures 2F–2H) or
RARa-fusion-transformed primary cells (Figures 2I–2K). As a
result, suppression of PHF8 conferred ATRA resistance in both
NB4 cells (Figure 2H) and RARa-fusion-transformed primary
cells (Figure 2K), although the effect was more pronounced in
the latter with a more defined genetic background. Together,
these results indicate that PHF8 may act as a sensor to mediate
ATRA response in APL and its level may govern ATRA sensitivity.
PHF8 Resensitizes ATRA-Resistant APL Cells In Vitro
and In Vivo
To investigate if PHF8 can indeed sensitize ATRA-resistant cells
to the treatment, we induced expression of wild-type PHF8 and
the catalytically dead mutant PHF8-F279S in the ATRA-resistant
NB4-MR2 cells (Figures S3A and S3B). NB4-MR2 cells have an
increased level of topoisomerase 2b (TOP2b) that could
decrease ATRA-mediated gene expression and granulocytic
differentiation by enhancing the association of repressor
complexes with PML-RARa downstream target genes including
RARB (McNamara et al., 2008). NB4-MR2-PHF8 cells showed
a significant reduction in colony number, induction of the
RARB expression, and increased differentiation of the APL cells
after ATRA treatment (Figures 3A–3C and S3C–S3E). On the
contrary, expression of PHF8-F279S failed to sensitize NB4-
MR2 cells to the treatment, indicating an important enzymatic-
activity-dependent function of PHF8, in governing ATRA
response even in resistant cells (Figures 3A–3C and S3A–S3E).
To further assess if PHF8 is also able to sensitize ATRA-resistant
cells to treatment in vivo, we transplanted NB4-MR2, NB4-MR2-
PHF8, and NB4-MR2-F279S cells into sublethally irradiated
NOD-SCID-Gamma (NSG) mice for in vivo leukemogenic assay
(Figures 3D and 3E). As expected, mice transplanted with
NB4-MR2 cells succumbed to leukemia regardless of ATRA
treatment. Strikingly, mice transplanted with NB4-MR2-PHF8
cells responded very well to the ATRA treatment, and most of
them remained healthy (Figure 3D). This was in stark contrast
to the untreated NB4-MR2-PHF8 control group that rapidly
succumbed to leukemia. Consistent with the in vitro results
(Figures 3A–3C), mice transplanted with NB4-MR2-F279S failed
to respond to the ATRA treatment in vivo and developed
leukemia with a similar latency as the untreated controls,
confirming the importance of its enzymatic activity in ATRA
response (Figure 3E). These results strongly indicate that PHF8
plays a critical role in mediating ATRA response, and its activa-
tion by an overexpression approach reverses ATRA resistance
in APL cells.
Another major mechanism for ATRA resistance in human APL
is the mutation of ligand binding domain (LBD) of PML-RARa
(Coˆte´ et al., 2000). To further extend the role of PHF8 in ATRA-
resistant APL, we employed two different APL models, namely,
human NB4-LR2 cells (Roussel and Lanotte, 2001) and primary
leukemic cells from a PML-RARam4 transgenic mouse (desig-
nated ‘‘M4’’ herein) (Kogan et al., 2000), each carrying a different
PML-RARa LBD mutation identified in human APL patients. As
expected, NB4-LR2 cells were resistant to ATRA (Figures 3F,
3G, and S3F–S3H). Conversely, expression of PHF8 resensitized
their response to ATRA 108 M (Figures 3F, 3G, and S3F–S3H).380 Cancer Cell 23, 376–389, March 18, 2013 ª2013 Elsevier Inc.However, this effect disappeared when the mutation abolishing
the catalytic activity was introduced to PHF8, consistently
indicating the critical function of PHF8 enzymatic activity in
mediating the ATRA response even in the PML-RARa LBD
mutant (Figures 3F and 3G, S3A, and S3F–S3H). Finally, trans-
plantation of NB4-LR2 cells into NGS mice induced ATRA-
resistant leukemia, which could, however, be sensitized to
ATRA treatment again when PHF8 was expressed (Figure 3H).
To further validate these results in a well-defined genetic back-
ground, we performed similar in vivo experiments using the
well-characterized ATRA-resistant M4 primary cell model
(Kogan et al., 2000). M4 cells induced leukemia in mice regard-
less ATRA treatment. M4 cells expressing PHF8 also induced
leukemia in mice. However, expression of active PHF8 in combi-
nation with ATRA treatment significantly extended the survival
of mice and induced differentiation of M4 cells (Figures 3I and
3J). Together, these results strongly indicate that activation of
PHF8 can resurrect ATRA sensitivity in a wide range of clinically
relevant ATRA-resistant APL cells.
PHF8 Switches Promoter Occupancy after ATRA
Treatment
It has been shown that the binding of PHF8 to its targets is regu-
lated by its phosphorylation status (Liu et al., 2010). PHF8 binds
to promoter regions of genes involved in cell cycle progression
such as RBL1 to remove H4K20me1 mark and dissociates
from these promoters upon phosphorylation of S33/S84 resi-
dues by CDK1 (Liu et al., 2010). To gain further insights into
the molecular regulation of PHF8 upon ATRA treatment in APL,
we investigated the dynamics of PHF8 promoter occupancy by
ChIP analysis in NB4-MR2 cells. Upon ATRA treatment, the
binding of PHF8 to the promoter regions of multiple RARa fusion
targets, includingRARB, PRAM1, TGM2, and ID1 (Martens et al.,
2010; Wang et al., 2010), was increased (Figure 4A), while its
binding to naive PHF8 targets such as RBL1 and CCNE1
promoters that are occupied by PHF8 in the absence of ATRA
was reduced (Figure 4B). ATRA treatment had no effect on the
binding of PHF8 at the control GAPDH promoter (Figure 4C).
This switch in promoter occupancy was also accompanied by
changes in corresponding histone marks. A significant reduction
in PHF8-specific repression marks (H3K9me2) and an increase
in activation marks (H3K4me3 and H3K9Ac) were detected in
the same promoter regions of RARB (Figure 4D), PRAM1
(Figure 4E), TGM2 (Figure 4F), and ID1 (Figure 4G), whereas
H4K20me1 histone mark was significantly increased at the
RBL1 (Figure 4I) and CCNE1 (Figure 4J) promoters. None of
these changes could be detected in the noncoding control
region (NC1) of NB4-MR2 cells (Figures 4H and 4K) or the
same RARB regions in K562 cells that do not carry RARa fusions
(Figures S4A and S4B). Thus, these findings suggest that PHF8
may switch promoter occupancy for driving the expression of
PML-RARa targets in human APL cells upon ATRA treatment.
PHF8-Mediated ATRA Response Is Regulated by Serine
Phosphorylation
Interestingly, ATRA is known to relocate cyclin A to the nuclear
compartment in leukemic cells, resulting in activation of CDK1
in AML cells (Ekberg et al., 2004). Thus, we speculated that
the promoter occupancy of PHF8 might be regulated by ATRA
Figure 3. PHF8 Sensitizes ATRA-Resistant APL Cells to Physiological Concentrations of ATRA
(A–H) Human APL cells transduced with vector control or PHF8 wild-type or its catalytically inactive mutant F279S were treated with and without ATRA at the
indicated concentrations. Typical INT-stained colony pictures of NB4-MR2 (A) and NB4-LR2 (F) cell lines. The bar charts represent NB4-MR2 normalized
numbers of colonies (B). Error bars are representative of four independent experiments. (±SEM, ***p < 0.001). qRT-PCR analysis for human RARB expression
in NB4-MR2 (C) or NB4-LR2 (G) cell lines. Error bars indicate SD of three independent experiments. Disease-free survival of NSG mice injected with NB4-MR2,
NB4-MR2-PHF8 cells (D), NB4-MR2-F279S cells (E), or NB4-LR2, NB4-LR2-PHF8 cells (H), with and without ATRA treatment.
(I and J) M4 cells from PML-RARa LBD transgenic mouse model transduced with vector control (control M4) or PHF8 wild-type (PHF8 M4). Disease-free survival
of FVBmice injected with control M4 or PHF8M4 cells with and without ATRA treatment. Black arrowheads indicate the end of ATRA treatment (I). FACS analysis
of bone marrow cells stained with Gr-1, Mac-1, and c-Kit markers for differentiation status of murine myeloid cells (J).
See also Figure S3.
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Figure 4. Changes of PHF8 Promoter Occupancy and Associated Histone Modifications after ATRA Induction
ChIP analysis of PHF8 (A–C) or various histone marks including H3K9me2, H3K4me3, H3K9Ac, H4K20me1 (D–K) on both RARa-fusion-targeted promoters (e.g.,
RARB,PRAM1, TGM2, and ID1) and naive PHF8-targeted promoters (e.g.,RBL1,CCNE1) before and after 24 hr of ATRA treatment at 0M or 108M in NB4-MR2-
PHF8 cells. ChIP signals are presented as percentage of input. Error bars indicate SD of three independent experiments (±SD, *p < 0.05, **p < 0.01). GAPDH
was used as negative control for PHF8 occupancy, and NC1 was used as negative control for histone marks. See also Figure S4.
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PHF8 Governs ATRA Response in APLin part by CDK1-mediated phosphorylation. Indeed, we de-
tected an increase in PHF8 phosphorylation with increasing
levels of ATRA in NB4-MR2-PHF8 cells (Figure 5A). Next, we
investigated if CDK1-mediated PHF8 phosphorylation would
be able to mimic ATRA response in PHF8-transduced NB4 or
NB4-MR2 cells (Figures 5B–5D, S5A, and S5B). In the absence
of ATRA treatment, cells transduced with PHF8 (NB4-MR2-
PHF8) or CDK1 (NB4-MR2-CDK1) exhibited a mild increase of
RARB gene expression as compared with vector-control (NB4-
MR2)-transduced cells (Figure 5B). In contrast, cells cotrans-
duced with CDK1 and PHF8 (NB4-MR2-CDK1-PHF8) signifi-
cantly activated RARB expression even in the absence of
ATRA (Figure 5B). These transcriptional activities also directly
correlated with the biological readouts, in which coexpression
of PHF8 with CDK1 significantly suppressed transformation382 Cancer Cell 23, 376–389, March 18, 2013 ª2013 Elsevier Inc.and enhanced differentiation of NB4-MR2 cells even in the
absence of ATRA treatment (Figures 5C and 5D). Similar results
could also be obtained for NB4 cells (Figure S5B). These results
suggest a critical function of CDK1 in mediating PHF8 func-
tions, although it is known that CDK1 can have many different
targets and functions, and likewise other kinases may also be
able to modulate PHF8 activity. To confirm the critical role of
PHF8 phosphorylation in mediating ATRA response, we gener-
ated two additional PHF8 variants at those two serine
phosphorylation sites by replacing S33 and S84 with either
alanines to generate a phosphorylation defective mutant
(PHF8AA) or aspartic acids to mimic a constitutively phosphor-
ylated form (PHF8DD) (Liu et al., 2010). To further demonstrate
their specific activity in mediating ATRA response, these three
PHF8 variants were fused to the ligand binding domain of the
Figure 5. PHF8-Mediated ATRA Response Is Regulated by Serine Phosphorylation
(A) PHF8 was immunoprecipitated from total cell lysate of NB4-MR2-PHF8 cells treated with the indicated concentrations of ATRA and immunoblotted for
phospho-Ser (upper panel); the membrane was stripped and then immunoblotted for total PHF8 protein (lower panel). The bar chart at the right represents
quantification of serine-phosphorylated PHF8 relative to the total PHF8 protein. Error bars represent SD of three independent experiments.
(B–D) NB4-MR2 cells were transduced with empty vector control, wild-type PHF8, wild-type CDK1, or PHF8 and CDK1 together. The RARB mRNA level
(B, measured by qRT-PCR, error bars indicate SD of three independent experiments), the number of colony formed (C, error bars represent SEM of three
independent experiments, ***p < 0.001), and expression of the differentiation marker for myeloid cells CD11b (D, FACS analysis) of these cells were determined.
(E) The number of colonies of NB4-MR2 cells transduced with ER-fused enzymatic active (left) or dead (right) PHF8, PHF8AA, or PHF8DD in the absence or
presence of 100 nM 4-OHT. Error bars represent three independent experiments (±SEM, **p < 0.01, ***p < 0.001).
(F) RARB mRNA level in cells transduced with indicated PHF8 constructs after induction with 100 nM 4-OHT shown in (E). Error bars indicate SD of three
independent experiments.
(G) FACS analysis for CD11b expression of NB4-MR2-ER cells expressing PHF8 or different PHF8 mutants.
(H) Typical INT-stained colony pictures of NB4-MR2 cells transduced with empty vector control, PHF8, PHF8AA, or PHF8DD.
(I) ChIP analysis comparing the PHF8 occupancy at the indicated promoter regions of NB4-MR2 cells transduced with PHF8AA and PHF8DD variants. ChIP
signals are presented as fold enrichment over MYOG (±SD, *p < 0.05, **p < 0.01).
(J) Representative coimmunoprecipitation (coIP) analysis in 293T cells. PML-RARawas coexpressed in the presence ofGFP-SMRT, Flag-PHF8, or Flag-PHF8DD.
(K) Disease-free survival curves of NSG mice injected with NB4-MR2 cells expressing PHF8AA or PHF8DD.
See also Figure S5.
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Figure 6. Okadaic Acid Specifically Inhibits PHF8 Dephosphorylation and Sensitizes NB4-MR2 Cells to ATRA Treatment
(A) Western blot analysis of PHF8 phosphorylation in NB4-MR2-PHF8 cells upon 10min treatment with 0.5 mMOKA. Flag-tagged PHF8 was immunoprecipitated
from the total lysate using anti-Flag antibody and blotted for phospho-Ser detection (upper panel) or for total PHF8 protein on the stripped membrane (lower
panel).
(B and C) The effect of OKA treatment on NB4-MR2 cells transduced with PHF8, PHF8AA, or PHF8DD. Cells were plated in methylcellulose after 10 min of OKA
pretreatment at the indicated concentrations without (B) or with (C) ATRA treatment. Data are representative of three independent experiments (±SEM, **p < 0.01,
***p < 0.001).
(D–G) K562 and NB4-MR2 cells were pretreated with OKA as described above and plated in methylcellulose with or without 108 M ATRA. The bar charts show
the number of colonies after indicated treatment for K562 (D) and NB4-MR2 (F), while INT-stained represent typical results for K562 (E) and NB4-MR2 (G) colony
formation assay. Data are representative of three independent experiments (±SEM, **p < 0.01).
(legend continued on next page)
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PHF8 Governs ATRA Response in APLestrogen receptor (ER) to allow an inducible activation of the
proteins by 4-hydroxy-tamoxifen (4-OHT) treatment. As ex-
pected, activation of PHF8 in the absence of ATRA had little
impact on NB4-MR2 cells, and similar results were obtained
for PHF8AA mutant (Figures 5E–5G, S5C, and S5D). However,
expression of PHF8DD mutant significantly suppressed colony
formation (Figure 5E) as well as enhanced expression of
RARB (Figure 5F) and differentiation (Figure 5G) of APL cells
without a significant impact on apoptosis (Figure S5D) even in
the absence of ATRA. These results from ER-inducible mutants
could also be directly reproduced using corresponding consti-
tutive mutants (Figure 5H), in which the PHF8AA mutant as
expected failed to collaborate with CDK1 for suppression of
NB4-MR2 colony formation in the absence of ATRA (Fig-
ure S5E). Moreover, PHF8DD as compared with PHF8AA
exhibited a much stronger binding to target promoters of
PML-RARa (e.g., RARB, PRAM1, TGM2, and ID1) but not the
MYOG control, consistent with a critical function of phosphory-
lation status in determining the promoter occupancy (Figure 5I).
To further investigate if the inhibitory effects by PHF8DD mutant
also require enzymatic activity of PHF8, the F279S mutation
was introduced to these three PHF8 variants. The F279S muta-
tion completely abolished both the transformation suppressive
function and the transactivation activity of PHF8DD (Figures
5E–5G), strongly suggesting that ATRA response mediated by
PHF8 is regulated by both serine phosphorylation and enzy-
matic activity of PHF8. Consistently, expression of PHF8DD
mutant but not wild-type PHF8 could displace the transcrip-
tional corepressor SMRT from PML-RARa in the absence of
ATRA (Figure 5J). To further demonstrate that phosphorylation
of PHF8 plays a key role in mediating ATRA response in APL
in vivo, NB4-MR2 cells expressing either PHF8AA or PHF8DD
mutant were transplanted into NSG mice for in vivo leukemo-
genic assay. PHF8DD significantly extended the disease
latency even in the absence of ATRA treatment, confirming
a key role of PHF8 phosphorylation status for APL leukemogen-
esis (Figure 5K).
Inhibition of PHF8 Dephosphorylation by Okadaic
Acid Sensitizes ATRA-Resistant Human APL Cells
to the Treatment
Considering the critical function of PHF8 in mediating ATRA
response, we asked if pharmacological inhibition of PHF8
dephosphorylation could sensitize resistant APL cells to the
ATRA treatment. To this end, we tested the effect of two
common phosphatase inhibitors, calyculin A and okadaic acid
(OKA), on NB4-MR2-PHF8 cells for their ability to suppress
dephosphorylation of PHF8. OKA showed good efficacy in
inhibiting PHF8 dephosphorylation as revealed by a significant
increase of PHF8 serine phosphorylation in NB4-MR2-PHF8
cells upon OKA treatment (Figure 6A; data not shown). Consis-
tent with this result, colony formation assays revealed that OKA
alone could suppress colony formation by NB4-MR2-PHF8
cells, while it had no effect on NB4-MR2 cells expressing phos-(H and I) NB4-MR2 cells were treated with OKA and ATRA as indicated and then
three independent experiments) or CD11b by FACS (I).
(J) Disease-free survival curves of NSG mice transplanted with NB4-MR2 cells a
See also Figure S6.phorylation mutants NB4-MR2-PHF8AA and NB4-MR2-
PHF8DD (Figure 6B). In addition, combined OKA/ATRA
treatment had further enhanced tumor suppression effect on
NB4-MR2-PHF8 cells but not on NB4-MR2 cells expressing
PHF8AA or PHF8DD mutants (Figure 6C), indicating a critical
function of these two PHF8 phosphorylation sites in mediating
OKA response. To further assess if OKA can be used to sensi-
tize ATRA-resistant APL to the treatment without genetic
manipulation of PHF8, NB4-MR2 cells and K562 control cells
were treated with OKA, ATRA, or their combination and sub-
jected to colony formation assay (Figures 6D–6I). As expected,
K562 cells did not respond to any of the treatments with ATRA,
OKA, or their combination (Figures 6D and 6E). NB4-MR2 cells
were also refractory to ATRA treatment and exhibited a very
mild response to OKA treatment alone (Figures 6F and 6G).
However, the combined treatment of ATRA and OKA could
significantly reduce the colony formation ability of NB4-MR2
cells (Figures 6F and 6G), which was also accompanied by
increased expression of RARB (Figure 6H) and expression of
differentiation marker CD11b (Figure 6I). Consistently, very
similar effects were also obtained using NB4 cells and NB4-
LR2 cells carrying wild-type and LBD mutant of PML-RARa
(Figures S6A and S6B), indicating a more general effect of
OKA on different ATRA-resistant APL cells. Finally, in order to
assess the in vivo efficacy of OKA/ATRA treatment on ATRA-
resistant APL, NB4-MR2 cells were transplanted into NSG
mice and subjected to the treatments. Mice receiving ATRA
or OKA treatment alone died at almost the identical time points
as the untreated control (Figure 6J). In contrast, combined OKA/
ATRA treatment significantly prolonged the survival of mice
even after ceasing treatment (Figure 6J). Together, these results
reveal PHF8 as a critical sensor in mediating ATRA response,
and pharmacological manipulation of its activity represents
a potential avenue to sensitize resistant APL cells to the ATRA
treatment.
DISCUSSION
Transcriptional deregulation plays a key role in a large array of
human cancer, in particular, in acute leukemia, which is mostly
initiated by mutations affecting master transcription factors
(Cheung and So, 2011). While development of small molecule
inhibitors targeting transcriptional machinery has been proved
extremely difficult, the discovery of epigenetic modifying
enzymes such as EZH2 and DNMT3 with rigid catalytic domains
that are mutated or aberrantly recruited by oncogenic transcrip-
tion factors for their functions have fueled the enthusiasm for
targeting these classically intractable factors (Zeisig et al.,
2012). This has also led to a recent burst of international efforts
in developing specific inhibitors toward these enzymes (Arrow-
smith et al., 2012). In addition to their emerging role in disease
development, here we reveal a critical function of KDM in regu-
lation of treatment response, in which PHF8 governs the ATRA
sensitivity in APL.analyzed for the expression of RARB by qRT-PCR (H, error bars indicate SD of
nd then treated as indicated. Arrow indicates the end point of the treatment.
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Figure 7. Schematic Diagram Illustrates the
Molecular Regulation of PHF8 in Mediating
ATRA Response in APL
In leukemia, PML-RARa (PR) recruits corepressor
complexes (CoR) to suppress expression of
downstream targets. Upon ATRA treatment, PHF8
is phosphorylated and detaches from the original
binding sites (naive PHF8 targets, e.g., RBL1
promoter) to bind to PR. PHF8 removes H3K9me2
marks and recruits additional histone modification
enzymes and RNA polymerase II (RNAPII) to drive
the expression of PR downstream targets (e.g.,
RARB) for differentiation.
Cancer Cell
PHF8 Governs ATRA Response in APLAlthough significant progress has been made in recent years
in characterizing the corepressor complexes and the resultant
epigenetic landscapes in APL cells (Martens et al., 2010; Wang
et al., 2010), the molecular basis and regulation of the resultant
transcriptional reactivation upon ATRA treatment are still largely
unknown (Mikesch et al., 2010). In this study, we provide several
lines of evidence that PHF8 functions as a critical coactivator and
molecular sensor in regulating transcriptional and cellular
responses to ATRA treatment in APL. In contrast to HDAC or
PRC2, PHF8 is differentially recruited by the RARa fusions to
remove repressive histone marks and favors active gene tran-
scription in response to ATRA treatment, which is in agreement
with PHF8 as a class of transcriptional coactivators recruited
by RARa fusions to create a more permissive chromatin environ-
ment at promoters in response to ATRA treatment (Figure 7).
Activation of PHF8 activity by increasing its level of either ex-
pression or phosphorylation at S33/S84 residues can sensitize
ATRA-responsive or ATRA-resistant APL. Under these condi-
tions, the respective demethylated lysine residues can be targets
for acetylation and additional interactions with RNA polymerases
and other proteins, which may further stimulate transcription
(Fortschegger et al., 2010). Consistently, inhibition of LSD1
resulting in an increase of H3K4me2 has recently been shown
to be able to reactivate ATRA differentiation pathway in AML
(Schenk et al., 2012), whereas histone acetylation has been
one of the highly regulated histone marks in RARE binding
sites with a strong correlationwith RNA polymerase II occupancy
near PML-RARa binding sites upon ATRA treatment (Martens
et al., 2010; Mikesch et al., 2010). Interestingly, inhibition of
TOP2b that overcame ATRA resistance in NB4-MR2 also caused
hyperaceylation of H3K9 (McNamara et al., 2008), which is
consistent with the observed transcriptional function of PHF8.
Thus, identification of PHF8 as a coactivator for RARa fusions
may provide a molecular explanation for epigenetic changes
associated with ATRA response and opens up promising
avenues to sensitize cancer cells to ATRA treatment.
RA signaling and subsequent activation of target genes for
induction of differentiation, cell cycle arrest, and apoptosis
have been a focus for development of differentiation-based
cancer therapy (Gronemeyer et al., 2004). ATRA and 13-cis RA386 Cancer Cell 23, 376–389, March 18, 2013 ª2013 Elsevier Inc.have been used in the clinic to treat cuta-
neous T cell lymphoma (CTCL) and
neuroblastoma (NB) by targeting endoge-
nous RAR to induce cell proliferationarrest and morphological differentiation in these tumors. While
RA treatment after completion of chemoradiotherapy signifi-
cantly improves event-free survival in high-risk NB patients (Mat-
thay et al., 2009), more than 40% of the patients will relapse, and
virtually all become resistant to the treatment. Interestingly,
PHF8 can also interact with endogenous RAR in the absence
of RARa fusions, and its knockdown suppresses RA-induced
neuronal differentiation from mouse embryonic P19 cells (Qiu
et al., 2010), suggesting its potential function in regulating RA
response in the neuronal lineage. This property is reminiscent
of ZNF423, which is activated by tumor suppressor NF1 (Ho¨lzel
et al., 2010) and is critically required for RA-induced differen-
tiation of NB cells (Huang et al., 2009). However, ZNF423
constitutively associates with RAR regardless of ATRA treat-
ment; thus, additional RA modulators (RAMs) that are differen-
tially recruited to RAR/RXR complexes are likely required to
mediate the RA response in NB. While PRAME has been re-
ported to differentially bind to RAR upon RA treatment, it acts
as a transcriptional repressor to prevent ligand-induced activa-
tion (Epping et al., 2005), and the equivalent positive RAM is still
missing. In analogy to PRAME, PHF8 is differentially recruited to
RAR in response to ATRA. Instead of complexing with EZH2 for
making transcriptional repressive marks (Epping et al., 2005),
PHF8 possesses enzymatic activity that can actively remove
repressive marks and recruits other epigenetic modifying
enzymes and basal transcriptional machinery for active gene
expression. Discovery of the critical functions of PHF8 in
ATRA-mediated transcriptional and in vivo cellular responses
in APL may also suggest PHF8 as the missing positive RAM.
While the activity of RAM is likely tissue specific and requires
other cofactors to mediate its full response, it will be of interest
to determine if PHF8 may fulfill the role of positive RAM in
mediating RA response in other cell types as well. As a proof-
of-principle study, we were able to show that combined treat-
ment of ATRA and OKA, a phosphatase inhibitor suppressing
PHF8 dephosphorylation, could be used successfully to treat
ATRA-resistant human APL cells in vivo. Together, these results
describe an important molecular regulation of PHF8 in mediating
ATRA response and raise hope to develop effective therapeutic
strategies combining ATRA treatment with drugs inducing
Cancer Cell
PHF8 Governs ATRA Response in APLspecific epigenetic modifications to target RA-resistant cancer
cells.
EXPERIMENTAL PROCEDURES
Plasmids and antibodies are described in Supplemental Experimental
Procedures.
Immunoprecipitation and Western Blot Analysis
For generic immunoprecipitation, transfected cells were lysed in 0.5% NP-40
lysis buffer (50 mM Tris-HCl [pH 8], 150 mM NaCl, 5 mM EDTA, 0.2 mM DTT,
10% glycerol, protease inhibitor, 0.5% NP-40 detergent) for mild conditions
or RIPA lysis buffer (50 mM Tris-HCL [pH 8], 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors) for stringent
condition during 1 hr at 4C. They were then incubated with the respective
antibody overnight, precipitated with protein A/G Dynal beads (Invitrogen) at
4C for 1 hr, and then washed with mild 0.5% NP-40 lysis buffer or stringent
RIPA buffer. The indicated amount of ATRA was present throughout the
processes. Eluted proteins were resolved by SDS-PAGE. Membranes were
probed with described antibodies.
Histone Purification
Nuclei were extracted in acidic conditions to selectively remove histones,
which were used subsequently for immunoblotting analysis. Details are in
Supplemental Experimental Procedures.
Immunofluorescence Staining
Cytospins of a total of 5 3 104 cells were performed onto glass microscope
slides and then fixed with 4% formaldehyde in phosphate-buffered saline
(PBS) (pH 7.4) for 30 min on ice. Cells were washed in PBS, permeabilized,
and blocked using 10% fetal calf serum (FCS)/1% BSA/0.2% TX-100/PBS
for 15 min. Anti-H3K4 was used at 1:50 dilution in 10% FCS/1% BSA/PBS
and incubated overnight at 4C. Slides were washed three times with
PBS and subsequently incubated with 1:100 donkey anti-mouse fluorescein
isothiocyanate for 30 min at room temperature. Slides were washed five
times with PBS and mounted with Vectashield (Vector Laboratories, Peterbor-
ough, UK).
Chromatin Immunoprecipitation
NB4, NB4-MR2, and K562 cells were cultured in R10 medium at 37C and,
when indicated, treated for 24 hr with 108 M ATRA and crosslinked with
1% formaldehyde (Sigma). Details are described in Supplemental Experi-
mental Procedures.
Retroviral/Lentiviral Transduction and Transformation Assays
Retroviral/lentiviral transduction and transformation assays (RTTAs) were
performed on primary murine or human hematopoietic cells as previously
described (Zeisig and So, 2009). In brief, c-kit+ cells were isolated frommurine
bone marrow and cultured overnight in R10 medium (RPMI 1640, 10% FCS,
2 mM L-glutamine) supplemented with 20 ng/ml SCF, 10 ng/ml IL-3, and
IL-6. Spinoculation was carried out by centrifugation at 800 3 g in the pres-
ence of 5 mg/ml polybrene (Sigma-Aldrich, UK) at 32C for 2 hr. Cells were
plated in M3231 methylcellulose medium (Stem Cell Technologies, Canada)
supplemented with recombinant murine 20 ng/ml SCF, 10 ng/ml IL-3, IL-6,
and GM-CSF (PeproTech EC, UK), and antibiotic on the following day.
Colonies were scored and replated every 7 days.
For human cell studies, cells were transduced as described before and kept
in R10 with appropriate antibiotics until cells were plated into methylcellulose
medium. Colonies were scored after 8 days of culture.
Flow Cytometric Analysis
Immunophenotypic analysis was performed by flow cytometric analysis using
fluorochrome-conjugated monoclonal antibody to human CD11b (PE/Cy5
anti-human CD11b Clone ICRF44 Biolegend). Protocols and reagents used
for murine cell analysis were as previously described (Yeung and So, 2009)
and detailed in Supplemental Experimental Procedures.In Vitro Drug Studies
Drug studies were carried out by pretreating cells at 3 3 103 cells/ml in R10
with different concentrations of Okadaic Acid (Sigma-Aldrich), 0, 100, 250,
and 500 nM at different time points 0, 5, 10, or 20 min. After washing, cells
were plated in 1 ml of methylcellulose in the absence or presence of 108
M ATRA (Sigma-Aldrich). Colony formation was examined after 8 days of
incubation at 37C in 5% CO2.
Animals and Drug Treatment Studies
All experimental procedures were approved by King’s College London
and conform to the UK Home Office regulations. NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (also termed NSG) (Shultz et al., 2005) or FVB mice were
used for transplantation experiments. Mice were given 2.5 Gy total body
gamma-irradiation and injected intravenously with up to 1 3 105 test cells.
For drug studies, all treatments commenced on the next day after injection
of cells. Mice were given intraperitoneal injection of daily 1 mg ATRA/g of
body weight (He et al., 1998) or/and 50 ng OKA/g of body weight every
other day.
Statistical Analysis
Two-tailed Student’s test was used to determine statistical significance for all
bar charts. The log-rank test and Gehan-Breslow-Wilcoxon test were used
to compare survival curves as previously described (Yeung et al., 2010). The
p values less than 0.05 were considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.02.014.
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